BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Aug. 5, 2004
View Archived Issues
Avera's Venture Round Gets $48M For Neuroscience Bid
Although going about the typical process for a biotechnology firm backward, Avera Pharmaceuticals Inc. proved it can make the model work, raising $48 million in a Series C round of venture capital funding. (BioWorld Today)
Read More
Ceregene Raises $32M, Sends CNS Therapies Toward Clinic
Read More
Kalypsys Plans To Advance Pipeline With $29M Series B
Read More
Alnylam Acquires Rights To VEGF Patents From Hybridon
Read More
Inex Loses GSK As Partner For Liposomal Cancer Drug
Read More
Other News To Note
Read More